Cormorant Asset Management, LP Morphic Holding, Inc. Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $6.01 Million - $10.9 Million	-175,000 Reduced 53.85%	150,000 $8.6 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $8.45 Million - $15.8 Million	325,000 New	325,000 $12.2 Million
Q4 2021 Feb 14, 2022	SELL	$43.27 - $65.72 $4.33 Million - $6.57 Million	-100,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$53.61 - $67.5 $4.81 Million - $6.06 Million	-89,774 Reduced 47.31%	100,000 $5.66 Million
Q2 2021 Aug 16, 2021	SELL	$45.13 - $64.99 $7.23 Million - $10.4 Million	-160,226 Reduced 45.78%	189,774 $10.9 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $4.47 Million - $12.7 Million	150,000 Added 75.0%	350,000 $22.1 Million
Q4 2020 Feb 16, 2021	SELL	$25.66 - $34.55 $1.28 Million - $1.73 Million	-50,000 Reduced 20.0%	200,000 $6.71 Million
Q3 2020 Nov 16, 2020	BUY	$22.51 - $30.11 $5.63 Million - $7.53 Million	250,000 New	250,000 $6.84 Million

140

38.7M

4.2K

200K

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.